Back to News
Market Impact: 0.42
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Source: zacks.com
Healthcare & Biotech
Amgen's dazodalibep met the primary endpoint in a Phase III study for systemic Sjogren's disease, demonstrating sustained improvement in disease activity through week 48. The positive late-stage data materially de-risks the program and supports a potential regulatory filing and future commercial opportunity in Sjogren's disease.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
AMGN0.82
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
- J&J presents patient data on nipocalimab for Sjögren’s disease
- Rent-a-grandchild: Businesses offering companions to elderly grow in India